SS

Steve Shuttleworth

Venture Partner, Samsara BioCapital, Palo Alto, California

Bourne End, England

Invests in

Stages:

Sectors:

Pharmaceuticals

San Francisco Bay Area

Locations:

Palo Alto, California

Min Investment:
$10,000,000.00
Max Investment:
$100,000,000.00
Target Investment:
$25,000,000.00

Skills

Drug Development

Pharmaceutical Industry

Medicinal Chemistry

Clinical Development

Technology Transfer

Organic Chemistry

Analytical Chemistry

Education

PhD
University of Liverpool
(1991 - 1994)
BSc (Hons)
University of Liverpool
(1988 - 1991)
St Edward's College, Liverpool
(1981 - 1988)

Work Experience

Samsara BioCapital

2019

Venture Partner
2019

Autobahn Labs, Inc.

2019

Scientific Advisor
2019

Wharf Biotech Consulting Ltd.

2021

Director
2021

Nalo Therapeutics, Inc.

2019 - 2024

CTO
2019 - 2024

Topspin Therapeutics Inc. (Now Integer Bio Inc.)

2020 - 2022

CEO and Co-Founder
2020 - 2022

Karus Therapeutics Limited

2008 - 2020

Chair of The Scientific Advisory Board
2019 - 2020
CSO, COO and Executive Director
2017 - 2019
CSO and Executive Director
2008 - 2017

The University of Manchester

2014 - 2020

Honorary Professor, Molecular & Clinical Cancer Sciences, School of Medical Science
2014 - 2020

HOX Therapeutics Limited

2019 - 2019

Non Executive Director
2019 - 2019

Cancer Research UK

2006 - 2008

Head of New Projects Development
2006 - 2008

Piramed Ltd.

2003 - 2006

Director of Chemistry
2003 - 2006